Coherus Oncology, Inc. (CHRS)

↓ Download CSV

CIK 0001512762 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Coherus Oncology, Inc. reported revenue of $42.17M, up 59.8% from the prior year. The company was profitable, with a net margin of 398.4%. It held $258.34M in total assets against $197.33M in total liabilities.

Key ratios (FY2025)

-429.5%
Operating margin
398.4%
Net margin
275.4%
Return on equity
+59.8%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$42.17M$26.39M$257.24M$211.04M$326.55M$475.82M$356.07M$0$1.56M$189.48M
Cost of Revenue$13.81M$8.73M$158.99M$70.08M$57.59M$37.67M$17.08M
Operating Income-$181.13M-$199.65M-$203.20M-$256.88M-$263.86M$156.32M$107.77M-$204.42M-$232.14M-$115.93M
Net Income$168.02M$28.51M-$237.89M-$291.75M-$287.10M$132.24M$89.83M-$209.34M-$238.17M-$127.34M
EPS (Diluted)$1.43$0.25$-2.53$-3.76$-3.81$1.62$1.23$-3.22$-4.48
Total Assets$258.34M$448.53M$629.60M$480.85M$679.33M$841.65M$408.93M$99.47M$162.61M$178.49M
Total Liabilities$197.33M$580.52M$823.03M$618.26M$581.61M$560.67M$303.71M$138.06M$132.08M$159.13M
Shareholders' Equity$61.01M-$131.99M-$193.43M-$137.42M$97.73M$280.97M$105.21M-$38.59M$30.54M$20.53M
Cash & Equivalents$88.88M$125.99M$102.89M$63.55M$417.19M$541.16M$177.67M$72.36M$126.91M$124.95M
Operating Cash Flow-$138.51M-$20.44M-$174.88M-$241.12M-$37.43M$154.15M$28.36M-$159.27M-$200.29M-$252.54M
Capital Expenditures$286.0K$2.04M$1.29M$7.23M$1.82M$789.0K$4.57M$6.51M
Shares Outstanding121.15M115.61M112.22M78.85M76.93M72.51M70.37M68.30M59.84M45.81M